

Kidney Foundation of Canada

Background, research projects, etc., 13:14-5
See also Witnesses

Killens, Thérèse (L—Saint-Michel—Ahuntsic)

Brand name drugs, 1:19-21
 Drug patents, 1:20
 Drug Prices Review Board, 1:38-9, 41
 Drugs and pharmaceuticals, 1:19, 37, 39-40
 Drugs and pharmaceuticals industry, 1:21-2, 37
 Eastman report, 1:37
 Patent Act (amdt.)(Bill C-22), 1:19-22, 37-43; 2:6-7
 Procedure and Committee business
 Agenda and procedure subcommittee
 M., 1:8
 M. (Kempling), 2:6-7
 Bills, 1:10
 Briefs, 2:6-7
 Meetings, 1:42
 Minister, 1:9
 Organization meeting, 1:7-10
 Provinces, 1:37

King, Joyce (United Senior Citizens of Ontario)

Patent Act (amdt.)(Bill C-22), 15:3, 54-68
 References *see* Drug plans—Ontario

Knight, Norman (Canadian Association of Social Workers)

Patent Act (amdt.)(Bill C-22), 11:61

L-Dopa *see* Drugs and pharmaceuticals**Lang, R.D. (Canadian Labour Congress)**

Patent Act (amdt.)(Bill C-22), 6:3, 48-60

Laskin, Right Hon. Bora *see* Drug Prices Review Board—Constitutionality**Lawsuits *see* Smith, Kline and French Canada Ltd.—Attorney General of Canada; United States****Lesick, William G. (PC—Edmonton East)**

Patent Act (amdt.)(Bill C-22), 4:15-6, 23
 Procedure and Committee business
 Bills, 4:16
 Witnesses, M. (White), 4:15-6, 23

Lexchin, Dr. Joel (Canadian Health Coalition)

Patent Act (amdt.)(Bill C-22), 7:3-17

Liberal government, former *see* Bill C-22—References**Licensing *see* Compulsory licensing****Lissak, Stan (Canadian Society of Industrial Pharmacists)**

Patent Act (amdt.)(Bill C-22), 15:3, 31-42

Lobbies *see* Multinational corporations; Pharmaceutical Manufacturers Association of Canada**Mackling, Hon. Alvin (Manitoba Government)**

Patent Act (amdt.)(Bill C-22), 15:3, 85-99
 References
 “Socialist” label, Kempling remark, 15:95-6
 See also Manitoba—Federal government

MacLeod, Stewart (Canadian Society for Clinical Investigation)

Patent Act (amdt.)(Bill C-22), 12:3, 29-30, 32-42

Madej, Barbara (Community Health Co-operative Federation of Saskatchewan)

Patent Act (amdt.)(Bill C-22), 11:3, 73

Mailloux, Terry A. (Pharmaceutical Manufacturers Association of Canada)

Patent Act (amdt.)(Bill C-22), 3:4, 46-9, 53, 57-61, 64, 68-9

Maitre, Manuel (Quebec Federation of Senior Citizens)

Patent Act (amdt.)(Bill C-22), 12:3, 16, 19-22, 24-8

Malaria *see* Diseases—Infectious**Malloy, S. (Federal Superannuates National Association)**

Patent Act (amdt.)(Bill C-22), 14:3, 62-3, 66-7

Malone, Arnold (PC—Crowfoot; Chairman)

Cystic fibrosis, 9:22
 Patent Act (amdt.)(Bill C-22), 9:21-2
 Procedure and Committee business
 Agenda and procedure subcommittee
 Establishing, M. (Killens), 1:8
 Reports, Ms. (Kempling), 2:5-7; 3:5
 Bills
 Amendments, 17:33
 Clause by clause study, 10:46-50; 11:32-4, 80-1; 12:76-7;
 15:99-100; 16:13, 20-1; 17:22, 43-5
 M. (White), 5:46, 49
 Amdt. (McCurdy), 4:31-2, 34
 M. (Orlikow), 11:34-8
 Amdt. (Tardif), 11:37-8
 M. (Orlikow), 15:69
 Translation, 1:9-10
 Briefs
 Deadline, 5:48
 Distribution, 3:5, 22-3; 10:47; 14:5-6, 33-4
 Chairman
 Appointment by Speaker, 1:6
 Role, 4:12-3
 Clerk, role, 4:23
 Corrigendum, Ms. (Bertrand), 17:18
 Information, requesting, 8:28
 Meetings
 Adjourning, 6:60
 M. (Dingwall), 4:34
 Scheduling, 1:41-3; 15:100
 M. (White), 5:46, 49
 Time limits, 16:10-1
 Members, privileges, 9:8-10
 M. (Dingwall), 9:23
 Membership, changes, 3:68; 4:18
 Minister, inviting, 1:8-10
 Motions, standing, 5:9
 Organization meeting, 1:6-10
 Printing, minutes and evidence, M. (Kempling), 1:7-8
 Proceedings, broadcasting, M. (Dingwall), 5:9-10
 Questioning of witnesses
 Order of questioners, 3:37, 52
 Time limit, 3:25-6
 Quorum, meeting and receiving/printing evidence without, 1:6
 Staff, hiring, M. (Kempling), 8:30
 Travel
 Authorization, 2:5-6
 Scheduling, 1:10
 Witnesses
 Appearances, 2:5, 7; 5:49; 8:30, 49; 9:5, 10, 22, 40-1; 10:47, 50
 M. (White), 4:5, 8, 10-1, 17; 5:46, 49
 Amdt. (Kempling), 4:25-8
 Amdt. (McCurdy), 4:28-31
 M. (Orlikow), 15:69
 Expenses, 2:6
 Inviting, 10:46; 14:5-6, 76-8